All

API

FDF

Price

Services

Excipients

Enquiries

Find

Active Pharmaceutical Ingredients
Finished Drug Formulations
Price
Excipients
Services
Marketplace

Market Place

Post Enquiry

Grow Your Pharma Business Digitally

Consultant-Needed-Insert

X

Find Clinical Drug Development Pipelines & Deals | PipelineProspector

All Data

Filters

refresh

×

FILTER DATA :

News Type

Company

Product Type

Deal Size

Upfront Payment

refresh

Product Type

Companies

Bionomics

Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

Australia

Post An Enquiry

AFSSI Connexions 2020

Participation Not Confirmed

Update your events

Bionomics Announces Financing Led by Apeiron Investment Group Ltd

Contact the Supplier

Lead Product(s): BNC210

Therapeutic Area: Psychiatry/Psychology Product Name: Undisclosed

Highest Development Status: Phase II Product Type: Small molecule

Partner/Sponsor/Collaborator: Apeiron Investment Group

Deal Size: $22.0 million Upfront Cash: Undisclosed

Deal Type: Financing June 02, 2020

Details:

The financing guarantees the Company's substantiated funding to advance Phase 2 clinical trials for the treatment of PTSD and other anxiety and stress-related disorders for its lead compound, BNC210.